For all their speedy sequencing of genomes, scientists have yet to figure out what all the DNA data mean about diseases, holding back the information from being used in patient treatment.
Denver-based market research startup GutCheck has found $4 million for a Series B round of financing.
Slow-moving regulators have kept the rules of engagement on social media platforms fuzzy for pharma players. Yet rather than sit on the sidelines waiting for the FDA to take a firm stance on dos and don'ts, many pharma companies have taken a shot at safe moves in the social realm. Potentially powerful collaboration tools have also attracted pharma groups, bringing scientists, patients and physicians into the same digital arenas to share ideas and partner on research. Read the report >>
Bill Gates has added his high-profile name and dollars to the open-science movement.
IMS Health has made its third cloud-based acquisition in as many months, snapping up mobile sales and marketing systems provider 360 Vantage. The deal continues IMS' whirlwind push into the cloud that has also seen it snag Appature and Semantelli in the past few months.
Merck's U.K. group has raised its level of play in an industry-wide competition for the attention of physicians as they use the Internet.
A survey of so-called health activists by Extrovertic and WEGO Health found that many patients with multiple sclerosis have an "insatiable appetite" for updated information
Tired of sifting through FDA warning letters for ideas about online-advertising boundaries? You're in luck. The Federal Trade Commission has issued new rules for social media and mobile ads.
Boehringer Ingelheim has expanded its reach in the world of digital healthcare via a new collaboration with the patient-focused social networking outfit PatientsLikeMe. The alliance is expected to "enhance" PatientsLikeMe's online community for idiopathic pulmonary fibrosis, an orphan lung disease without a known cause or cure.
Pharma now has another hint about FDA's attitudes toward social media. In a recent warning letter to supplement maker AMARC Enterprises, FDA took issue with the company's use of Facebook's "Like" feature. Apparently, the company "Liked" a questionable user testimonial--and the agency didn't like it.